334 results on '"Appelbaum F"'
Search Results
2. Bone marrow transplantation for leukaemia--current status and strategies for improvement.
- Author
-
Appelbaum FR
- Subjects
- Acute Disease, Humans, Immunosuppressive Agents therapeutic use, Leukemia genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery, Leukemia, Myeloid surgery, Polymorphism, Genetic, Treatment Outcome, Bone Marrow Transplantation, Leukemia surgery
- Abstract
Thirty-five years ago, bone marrow transplantation was first being explored as a last-ditch effort to treat patients with end stage leukaemia. Through the efforts of a large number of laboratory and clinical scientists, the application of transplantation has broadened and outcomes have dramatically improved. The science of transplantation continues to attract a great deal of research, and with this effort we can expect continued progress and patient benefit. more...
- Published
- 2004
Catalog
3. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience.
- Author
-
Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, Deeg HJ, Appelbaum FR, Anasetti C, Storb R, and Sanders JE
- Subjects
- Adolescent, Anemia, Sideroblastic therapy, Child, Child, Preschool, Chromosomes, Human, Pair 7 genetics, Female, Graft vs Host Disease etiology, Humans, Infant, Leukemia, Myelomonocytic, Acute genetics, Leukemia, Myelomonocytic, Chronic therapy, Male, Monosomy, Myelodysplastic Syndromes genetics, Survival Rate, Transplantation, Homologous, Washington, Bone Marrow Transplantation adverse effects, Leukemia, Myelomonocytic, Acute therapy, Myelodysplastic Syndromes therapy
- Abstract
The purpose of this study was to evaluate the role of allogeneic bone marrow transplantation (BMT) in children with myelodysplastic syndrome (MDS). In total, 94 consecutive pediatric patients with MDS received an allogeneic BMT from 1976 to 2001 for refractory anemia (RA) (n=25), RA with ringed sideroblasts (RARS) (n=2), RA with excess blasts (RAEB) (n=20), RAEB in transformation (RAEB-T) (n=14), juvenile myelomonocytic leukemia (JMML) (n=32) or chronic myelomonocytic leukemia (CMML) (n=1). The estimated 3-year probabilities of survival, event-free survival (EFS), nonrelapse mortality and relapse were 50, 41, 28 and 29%, respectively. Patients with RA/RARS had an estimated 3-year survival of 74% compared to 68% in those with RAEB and 33% in patients with JMML/CMML. In multivariable analysis, patients with RAEB-T or JMML were 3.9 and 3.7 times more likely to die compared to those with RA/RARS and RAEB (P=0.005 and 0.004, respectively). Patients with RAEB-T were 5.5 times more likely to relapse (P=0.01). The median follow-up among the 43 surviving patients is 10 years (range 1-25). We conclude that allogeneic BMT for children with MDS is well tolerated and can be curative. more...
- Published
- 2004
- Full Text
- View/download PDF
4. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.
- Author
-
Storek J, Joseph A, Espino G, Dawson MA, Douek DC, Sullivan KM, Flowers ME, Martin P, Mathioudakis G, Nash RA, Storb R, Appelbaum FR, and Maloney DG
- Subjects
- Adolescent, Adult, Antibodies, Bacterial blood, B-Lymphocytes, CD4 Lymphocyte Count, CD8-Positive T-Lymphocytes, Child, Child, Preschool, Female, Flow Cytometry, Haemophilus influenzae immunology, Humans, Immunoglobulin G blood, Infections epidemiology, Killer Cells, Natural, Leukocyte Count, Lymphocyte Count, Male, Monocytes, Polymerase Chain Reaction, Streptococcus pneumoniae immunology, Surveys and Questionnaires, Time Factors, Tissue Donors, Transplantation, Homologous, Transplantation, Isogeneic, Bone Marrow Transplantation immunology, Bone Marrow Transplantation mortality, Immunity
- Abstract
The duration of immunodeficiency following marrow transplantation is not known. Questionnaires were used to study the infection rates in 72 patients surviving 20 to 30 years after marrow grafting. Furthermore, in 33 of the 72 patients and in 16 donors (siblings who originally donated the marrow) leukocyte subsets were assessed by flow cytometry. T-cell receptor excision circles (TRECs), markers of T cells generated de novo, were quantitated by real-time polymerase chain reaction. Immunoglobulin G(2) (IgG(2)) and antigen-specific IgG levels were determined by enzyme-linked immunosorbent assay. Infections diagnosed more than [corrected] 15 years after transplantation occurred rarely. The average rate was 0.07 infections per patient-year (one infection every 14 years), excluding respiratory tract infections, gastroenteritis, lip sores, and hepatitis C. The counts of circulating monocytes, natural killer cells, B cells, CD4 T cells, and CD8 T cells in the patients were not lower than in the donors. The counts of TREC(+) CD4 T cells in transplant recipients younger than age 18 years (at the time of transplantation) were not different from the counts in their donors. In contrast, the counts of TREC(+) CD4 T cells were lower in transplant recipients age 18 years or older, even in those with no history of clinical extensive chronic graft-versus-host disease, compared with their donors. The levels of total IgG(2) and specific IgG against Haemophilus influenzae and Streptococcus pneumoniae were similar in patients and donors. Overall, the immunity of patients surviving 20 to 30 years after transplantation is normal or near normal. Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible. more...
- Published
- 2001
- Full Text
- View/download PDF
5. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial.
- Author
-
Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, and Martin PJ
- Subjects
- Adult, Biopsy, Chronic Disease, Disease-Free Survival, Female, Graft vs Host Disease pathology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Humans, Male, Prospective Studies, Risk Factors, Skin pathology, Survival Rate, Time Factors, Transplantation, Homologous, Bone Marrow Transplantation mortality, Cyclosporine administration & dosage, Graft vs Host Disease prevention & control
- Abstract
This study compared the incidence of clinical extensive chronic graft-versus-host disease (GVHD), transplantation-related mortality, survival, and relapse-free survival among recipients randomly assigned to receive a 24-month or a 6-month course of cyclosporine prophylaxis after transplantation of allogeneic marrow from an HLA-identical sibling or alternative donor. Patients who did not have clinical manifestations of chronic GVHD on day 80 after transplantation were eligible for the study if they previously had acute GVHD or if a skin biopsy showed histologic evidence of chronic GVHD. Clinical extensive chronic GVHD developed in 35 of the 89 patients (39%) in the 24-month group and 37 of the 73 patients (51%) in the 6-month group. The hazard of developing chronic GVHD was not significantly different in the 2 groups (hazard ratio = 0.76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival. more...
- Published
- 2001
- Full Text
- View/download PDF
6. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
- Author
-
Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, Edmands S, Flowers ME, Kerkof K, Nelson R, and Appelbaum FR
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Fusion Proteins, bcr-abl genetics, Humans, Kinetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism, Male, Middle Aged, Neoplasm Recurrence, Local, RNA, Neoplasm biosynthesis, Risk Factors, Bone Marrow Transplantation, Fusion Proteins, bcr-abl biosynthesis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
- Abstract
The bcr-abl chimeric messenger RNA is frequently detected in chronic myeloid leukemia (CML) patients after bone marrow transplantation. It was previously reported that the relapse risk of bcr-abl detection 6 to 12 months after transplantation was greater than 40%. This risk decreased as the time between transplantation and detection increased. To further define the relapse risk associated with bcr-abl molecular detection in "late" CML survivors, 379 consecutive CML patients alive at 18 months after transplantation or later were studied. Ninety of 379 patients (24%) had at least one positive bcr-abl test 18 months after transplantation or later; 13 of 90 bcr-abl-positive patients (14%) and 3 of 289 bcr-abl-negative patients (1.0%) relapsed. The median time from bcr-abl detection to relapse was 916 days (range, 251-2654 days). The hazard ratio of relapse associated with bcr-abl detection was 19.2 (P <.0001). The stage of disease, chronic graft-versus-host disease, and the donor type did not alter the association between bcr-abl and relapse. Quantification of bcr-abl was performed on 344 samples from 85 bcr-abl-positive patients by means of a real-time quantitative reverse transcriptase-polymerase chain reaction assay. The median bcr-abl change of patients who relapsed was significantly greater than those that remained in remission (P =.002). The median bcr-abl level at relapse was 40 443 bcr-abl copies per microg RNA (range, 960-299 552). Of 73 bcr-abl-positive patients who failed to relapse, 69% had only one positive test at a median of 24 copies bcr-abl per microg RNA. The detection of bcr-abl is common following transplantation. The prognostic significance of a qualitative bcr-abl can be refined by quantitative assays and thus may target patients who would benefit from early intervention. more...
- Published
- 2001
- Full Text
- View/download PDF
7. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
- Author
-
Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger W, Flowers ME, Martin P, Storb R, Appelbaum FR, and Boeckh M
- Subjects
- Adult, B-Lymphocytes immunology, CD4 Lymphocyte Count, Female, Filgrastim, Granulocyte Colony-Stimulating Factor pharmacology, Herpesvirus 3, Human immunology, Humans, Immunoglobulin G blood, Infections epidemiology, Infections immunology, Leukocyte Common Antigens analysis, Leukocyte Count, Lymphocyte Activation, Lymphocyte Count, Lymphocyte Subsets, Male, Middle Aged, Neutrophils, Phytohemagglutinins pharmacology, Recombinant Proteins, Simplexvirus immunology, T-Lymphocytes immunology, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Immunity
- Abstract
Allogeneic peripheral blood stem cell grafts contain about 10 times more T and B cells than marrow grafts. Because these cells may survive in transplant recipients for a long time, recipients of blood stem cells may be less immunocompromised than recipients of marrow. Immune reconstitution was studied in 115 patients randomly assigned to receive either allogeneic marrow or filgrastim-mobilized blood stem cell transplantation. Between day 30 and 365 after transplantation, counts of most lymphocyte subsets were higher in the blood stem cell recipients. The difference was most striking for CD4 T cells (about 4-fold higher counts for CD45RA(high) CD4 T cells and about 2-fold higher counts for CD45RA(low/-)CD4 T cells; P <.05). On assessment using phytohemagglutinin and herpesvirus antigen-stimulated proliferation, T cells in the 2 groups of patients appeared equally functional. Median serum IgG levels were similar in the 2 groups. The rate of definite infections after engraftment was 1.7-fold higher in marrow recipients (P =.001). The rate of severe (inpatient treatment required) definite infections after engraftment was 2.4-fold higher in marrow recipients (P =.002). The difference in the rates of definite infections was greatest for fungal infections, intermediate for bacterial infections, and lowest for viral infections. Death associated with a fungal or bacterial infection occurred between day 30 and day 365 after transplantation in 9 marrow recipients and no blood stem cell recipients (P =.008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389) more...
- Published
- 2001
- Full Text
- View/download PDF
8. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest.
- Author
-
Al-Ghamdi H, Leisenring W, Bensinger WI, Nash RA, Storb R, Appelbaum FR, and Martin PJ
- Subjects
- Acute Disease, Adult, Chi-Square Distribution, Female, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation mortality, Humans, Intestinal Diseases etiology, Leukemia mortality, Liver Diseases etiology, Male, Middle Aged, Morbidity, Prospective Studies, Regression Analysis, Skin Diseases etiology, Transplantation Conditioning, Treatment Outcome, Bone Marrow Transplantation, Graft vs Host Disease complications, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia therapy
- Abstract
The assessment of graft-versus-host disease (GVHD) as an end-point in clinical trials requires subjective judgement to distinguish morbidity caused by GVHD from morbidity caused by other complications. We developed a method based on ordinal regression for longitudinal assessment of morbidity involving the skin, liver and gut, regardless of cause as an objective end-point in randomized prospective phase III treatment or prevention trials for which GVHD is an outcome of interest. This method was validated for treatment studies by showing that morbidity was more severe among patients with grade II-IV GVHD than among those who did not have GVHD. We found no differences in morbidity involving the skin, liver and gut after the diagnosis of GVHD in a group of 30 patients who received peripheral blood stem cells and a group of 37 who received marrow in a randomized phase III clinical trial. These preliminary results suggest that objective end-points could be used in randomized clinical trials for treatment of GVHD. Further studies will be needed to determine if similar methods could be used in randomized clinical trials for prevention of GVHD. more...
- Published
- 2001
- Full Text
- View/download PDF
9. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation.
- Author
-
Rowley SD, Donaldson G, Lilleby K, Bensinger WI, and Appelbaum FR
- Subjects
- Adolescent, Adult, Child, Female, Filgrastim, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Male, Middle Aged, Patient Compliance, Recombinant Proteins, Transplantation, Homologous, Blood Donors, Bone Marrow Transplantation, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation
- Abstract
The experiences of 69 (38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating in a randomized trial comparing allogeneic bone marrow with PBSC transplantation were studied. Marrow was collected by means of standard harvest techniques and general or regional anesthesia. PBSC donors were treated with 5 to 7 days of filgrastim at a dose of 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram recipient weight. Donors completed questionnaires describing their health experiences before, during, and then weekly after donation until return to baseline status. Both marrow and PBSC donors reported minimal fluctuation in symptoms measuring emotional status. In contrast, both groups of donors reported deterioration in physical status starting with administration of filgrastim (PBSC donors) or after the marrow collection procedure. The symptom burden reported was similar, with pain a prominent symptom for both groups. Equivalent mean levels of maximal pain, average pain, and pain duration through the day were reported, although toxicity peaks occurred at different time points during the harvest procedures. All PBSC donors but only 79% of marrow donors reported good physical status by 14 days after the harvest procedures. These data demonstrate similar levels of physical discomfort for hematopoietic stem cell donors regardless of the collection procedure used, but a quicker resolution of symptoms for PBSC donors. more...
- Published
- 2001
- Full Text
- View/download PDF
10. Who should be transplanted for AML?
- Author
-
Appelbaum FR
- Subjects
- Humans, Bone Marrow Transplantation, Leukemia, Myeloid, Acute therapy
- Published
- 2001
- Full Text
- View/download PDF
11. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
- Author
-
Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers ME, Lilleby K, Chauncey TR, Storb R, and Appelbaum FR
- Subjects
- Adolescent, Adult, Cause of Death, Child, Combined Modality Therapy, Disease-Free Survival, Female, Filgrastim, Graft vs Host Disease epidemiology, Granulocyte Colony-Stimulating Factor therapeutic use, Hematologic Neoplasms drug therapy, Hematologic Neoplasms mortality, Hematologic Neoplasms radiotherapy, Hematopoietic Stem Cell Mobilization methods, Histocompatibility Testing, Humans, Incidence, Male, Middle Aged, Recombinant Proteins, Survival Analysis, Transplantation, Homologous, Bone Marrow Transplantation, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Background: In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) engraft more rapidly than bone marrow. However, the relative effects of these techniques on the rates of acute and chronic graft-versus-host disease, overall survival, and disease-free survival have not been determined in randomized studies., Methods: Between March 1996 and July 1999, 172 patients (12 to 55 years of age) with hematologic cancer were randomly assigned to receive either bone marrow or filgrastim-mobilized peripheral-blood cells from HLA-identical relatives for hematopoietic rescue after the treatment of hematologic cancer with high doses of chemotherapy, with or without radiation., Results: The recovery of both neutrophils and platelets was faster with peripheral-blood cells than with marrow (P<0.001 for both comparisons). The cumulative incidence of grade II, III, or IV acute graft-versus-host disease at 100 days was 64 percent with peripheral-blood cells and 57 percent with marrow (hazard ratio, 1.21; 95 percent confidence interval, 0.81 to 1.81; P=0.35). The cumulative incidence of chronic graft-versus-host disease was 46 percent with peripheral-blood cells and 35 percent with marrow (hazard ratio, 1.16; 95 percent confidence interval, 0.71 to 1.90; P=0.54). The estimated overall probability of survival at two years was 66 percent with peripheral-blood cells and 54 percent with marrow (hazard ratio for death, 0.62; 95 percent confidence interval, 0.38 to 1.02; P=0.06). The rate of disease-free survival at two years was 65 percent with peripheral-blood cells and 45 percent with marrow (hazard ratio for relapse or death, 0.60; 95 percent confidence interval, 0.38 to 0.95; P=0.03)., Conclusions: In patients given high-dose chemotherapy, with or without radiation, for the treatment of hematologic cancer, allogeneic peripheral-blood cells used for hematopoietic rescue restore blood counts faster than allogeneic bone marrow, without increasing the risk of graft-versus-host disease. more...
- Published
- 2001
- Full Text
- View/download PDF
12. American Society for Blood and Marrow Transplantation guidelines for training.
- Author
-
Shpall E, Adkins D, Appelbaum F, Keating A, LeMaistre CF, Mangen K, and Smith F
- Subjects
- Hematology education, Medical Oncology education, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation
- Published
- 2001
- Full Text
- View/download PDF
13. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.
- Author
-
Anderson JE, Appelbaum FR, Schoch G, Barnett T, Chauncey TR, Flowers ME, and Storb R
- Subjects
- Adult, Aged, Anemia, Refractory mortality, Anemia, Refractory surgery, Cyclophosphamide therapeutic use, Disease-Free Survival, Female, Graft vs Host Disease epidemiology, Humans, Male, Middle Aged, Radiotherapy, Adjuvant, Recurrence, Transplantation Chimera, Transplantation, Homologous, Treatment Outcome, Anemia, Refractory radiotherapy, Bone Marrow Transplantation, Liver, Lung, Radiation Protection, Whole-Body Irradiation adverse effects
- Abstract
Patients with the refractory anemia (RA) subtype of myelodysplastic syndrome who undergo allogeneic bone marrow transplantation (BMT) have a low risk of relapse, but they have a high risk of nonrelapse mortality when prepared with conventional preparative regimens. To try to reduce nonrelapse mortality, we treated 14 RA patients with a modified approach to total body irradiation (TBI) followed by cyclophosphamide (CY) and HLA-identical sibling BMT. Median patient age was 44 years (range, 28 to 65 years). Patients received TBI with shielding of the right lobe of the liver and both lungs followed by electron beam boosts to shielded ribs. Total radiation exposure in nonshielded areas was 12 Gy (n = 10), 10 Gy (n = 3), or 6 Gy (n = 1). After TBI, patients received CY at 120 mg/kg over 2 days, followed by transplantation of unmanipulated bone marrow. All patients initially achieved engraftment with donor cells, although 2 patients had subsequent reemergence of host hematopoiesis without evidence of disease relapse. Five patients died of transplantation-related causes between 22 and 1262 days post-BMT. Four patients relapsed between 157 and 1096 days post-BMT. These 14 patients were compared with 46 historical controls with RA who received conventional CY/TBI or busulfan/CY preparative regimens. Patients in the experimental group had a similar nonrelapse mortality rate compared with the historical control group (29% versus 37%, respectively; P = .8), but a higher relapse rate (34% versus 2%, P = .0004) and a lower disease-free survival (38% versus 61%, P = .16). We conclude that this modified TBI approach is associated with an unacceptably high risk of relapse for patients with RA undergoing BMT. more...
- Published
- 2001
- Full Text
- View/download PDF
14. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.
- Author
-
Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, Matthews D, Sanders JE, Storb R, Appelbaum FR, and Anasetti C
- Subjects
- Acute Disease, Adolescent, Adult, Bone Marrow Transplantation standards, Child, Child, Preschool, Disease-Free Survival, Female, Follow-Up Studies, Graft Survival, Graft vs Host Disease drug therapy, Graft vs Host Disease prevention & control, Humans, Infant, Leukemia, Myeloid complications, Male, Middle Aged, Prospective Studies, Recurrence, Survival Rate, Tissue Donors, Transplantation Conditioning, Treatment Outcome, Washington, Bone Marrow Transplantation methods, Leukemia, Myeloid therapy
- Abstract
Between 1985 and 1998, 161 patients with primary acute myeloid leukemia (AML) received T-replete bone marrow transplantation (BMT) from unrelated donors in Seattle. Median age was 30 (range 1-55) years. Conditioning for BMT consisted of cyclophosphamide and total body irradiation in 154 (96%) cases and graft-versus-host disease prophylaxis was the standard methotrexate and cyclosporine combination in 134 (83%) cases. Median post-transplant follow-up was 2.9 years. Leukemia-free survival (LFS) at 5 years was 50+/-12% for transplants during first complete remission (n = 16), 28+/-8% during second CR (n = 40), 27+/-17% during subsequent CR (n = 8), 7+/-3% during relapse (n = 81) and 19+/-10% during primary induction failure (n = 16). The cumulative incidences of relapse were 19%, 23%, 25%, 44% and 63%, for the five groups, respectively. Transplantation during remission, a marrow cell dose above 3.5 x 10(8)/kg, and cytomegalovirus seronegative status before BMT in both patient and donor were favorable prognostic factors. Adults in any CR who received a marrow cell dose above 3.5 x 10(8)/mg had a LFS of 54+/-9% at 5 years. These data extend our previous findings on the association between a high marrow cell dose and improved survival and support the use of unrelated donor BMT for treatment of patients with high risk AML when a family match is not available. more...
- Published
- 2000
- Full Text
- View/download PDF
15. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation.
- Author
-
Zang DY, Deeg HJ, Gooley T, Anderson JE, Anasetti C, Sanders J, Myerson D, Storb R, and Appelbaum F
- Subjects
- Adolescent, Adult, Antilymphocyte Serum therapeutic use, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease, Humans, Infant, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive radiotherapy, Male, Middle Aged, Probability, Proportional Hazards Models, Recurrence, Time Factors, Transplantation Conditioning methods, Transplantation, Homologous, Treatment Outcome, Whole-Body Irradiation, Bone Marrow Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery
- Abstract
We evaluated the outcome of allogeneic bone marrow transplantation (BMT) in 21 patients with chronic myelomonocytic leukaemia (CMML) who were treated at the Fred Hutchinson Cancer Research Center between 1990 and 1998. There were 11 male and 10 female patients with a median age of 47.4 years (range 1.0-62.9). Patients were conditioned either with total body irradiation (TBI) and chemotherapy, with or without antithymocyte globulin (n = 19), or with chemotherapy alone (n = 2). The marrow donor was an HLA-identical sibling in 12 patients, an HLA-non-identical related donor in three patients and an unrelated volunteer donor in six patients. All evaluable patients achieved sustained engraftment. Fifteen patients developed grades II-IV acute graft-versus-host disease (GVHD). Nine patients (43.0%) are surviving disease free at 0.7-8.1 years (median 6.9) after transplantation. Five patients relapsed 75-660 d after transplant and all died. Five patients died with organ failure and two died with GVHD and associated infections. The Kaplan-Meier estimates of disease-free survival and relapse at 3 years were 39% and 25% respectively. The probability of survival was improved in patients with shorter disease duration compared with those with a long interval from diagnosis to BMT. Thus, as with other myeloproliferative diseases or myelodysplastic syndromes, BMT offers curative therapy for a proportion of patients with CMML. We suggest that patients with CMML who have a suitable donor should be considered for transplantation, probably early in their disease course. However, it will be important to develop new regimens with enhanced antileukaemic efficacy without further increasing regimen-related toxicity and mortality. more...
- Published
- 2000
- Full Text
- View/download PDF
16. Is there a best transplant conditioning regimen for acute myeloid leukemia?
- Author
-
Appelbaum FR
- Subjects
- Acute Disease, Age Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials, Phase II as Topic, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Cyclophosphamide therapeutic use, Disease-Free Survival, Etoposide administration & dosage, Etoposide adverse effects, Etoposide therapeutic use, Graft Survival, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Humans, Immunosuppression Therapy methods, Randomized Controlled Trials as Topic, Thiotepa administration & dosage, Thiotepa adverse effects, Thiotepa therapeutic use, Whole-Body Irradiation adverse effects, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid therapy, Transplantation Conditioning methods
- Abstract
The outcome of marrow transplantation is largely determined by the effectiveness of the transplant preparative regimen. Nonetheless, there have been startlingly few randomized trials attempting to identify optimal regimens for specific conditions and, at present, no single approach has emerged as superior for the treatment of acute myeloid leukemia (AML) in the few trials that have been performed. Newer approaches that appear encouraging in phase II studies include substituting etoposide for cyclophosphamide, adding thiotepa to the traditional cyclophosphamide plus total body irradiation combination in the setting of T cell depletion, and using antibody-based targeted radiotherapy as part of the transplant regimen. The ability to obtain allogeneic engraftment with nonablative regimens may open the door to additional innovative approaches, combining very specific antileukemia therapy with relatively nontoxic measures to ensure engraftment. more...
- Published
- 2000
- Full Text
- View/download PDF
17. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.
- Author
-
Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, and Appelbaum FR
- Subjects
- Aged, Anemia, Refractory, with Excess of Blasts mortality, Anemia, Refractory, with Excess of Blasts therapy, Cyclophosphamide therapeutic use, Dose Fractionation, Radiation, Graft vs Host Disease prevention & control, Humans, Immunosuppression Therapy methods, Living Donors, Middle Aged, Myelodysplastic Syndromes mortality, Recurrence, Retrospective Studies, Survival Analysis, Time Factors, Whole-Body Irradiation, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes therapy, Transplantation, Homologous immunology, Transplantation, Isogeneic immunology
- Abstract
We carried out bone marrow transplantation (BMT) in 50 patients with myelodysplastic syndrome (MDS) who were 55.3 to 66.2 years of age (median, 58.8 years). According to the criteria of the French-American-British (FAB) classification, 13 patients had refractory anemia (RA), 19 had RA with excess blasts (RAEB), 16 had RAEB in transformation or acute myelogenous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (CMML). According to the recently established International Prognostic Scoring System (IPSS), available for 45 patients, 2 patients were considered low risk; 14, intermediate 1 risk; 19, intermediate 2 risk; and 10, high risk. Conditioning regimens were cyclophosphamide (CY) (120 mg/kg of body weight) plus 12-Gy fractionated total-body irradiation (FTBI) (n = 15), CY plus FTBI with lung and liver shielding (n = 4), busulfan (7 mg/kg) plus FTBI (n = 4), or busulfan (16 mg/kg) plus CY (n = 27). The busulfan-plus-CY group included 16 patients in whom busulfan was targeted to plasma levels of 600 to 900 ng/mL. In these 16 patients, steady-state levels of busulfan actually achieved were 714 to 961 ng/mL (mean +/- SD, 845 +/- 64 ng/mL; median, 838 ng/mL). The donors were HLA-identical siblings for 34 patients, HLA-nonidentical family members for 4, identical twins for 4, and unrelated volunteers for 6. All 46 patients surviving > 21 days had engraftment, and 22 patients (44%) are surviving 9 to 80 months after BMT. Specifically, among 13 patients with RA, 1 had relapse (cumulative incidence [CI] at 3 years, 8%) and 8 are surviving, for a Kaplan-Meier (KM) estimate of survival at 3 years of 59% (disease-free survival [DSF], 53%). Among 19 patients with RAEB, 3 had relapse (CI at 3 years, 16%), and 8 are surviving disease free (KM estimate at 3 years, 46%). Among 18 patients with RAEB-T/AML or CMML, 6 had relapse (CI at 3 years, 28%), and the KM estimate of DSF at 3 years is 33%. Relapse-free survival had an inverse correlation with cytogenetic risk classification and with the risk score according to the IPSS. Survival in all FAB categories was highest among patients enrolled in a protocol in which busulfan plasma levels were targeted to 600 to 900 ng/mL. These data indicate that BMT can be carried out successfully in patients with MDS who are older than 55 years of age. (Blood. 2000;95:1188-1194) more...
- Published
- 2000
18. Second allogeneic transplantation after failure of first autologous transplantation.
- Author
-
Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, and Appelbaum FR
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Hematologic Neoplasms pathology, Humans, Infant, Middle Aged, Recurrence, Salvage Therapy, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation, Hematologic Neoplasms therapy
- Abstract
We evaluated the outcome of second allogeneic bone marrow transplantations (BMTs) in 59 patients aged 1-57 years who relapsed after initial autologous transplantation. Patients received a second transplantation for recurrent acute myeloid leukemia (AML) (n = 24), acute lymphoblastic leukemia (ALL) (n = 13), lymphoma (n = 18), multiple myeloma (n = 3), or chronic myelogenous leukemia (n = 1) from an HLA-matched related (n = 14), mismatched related (n = 25), or matched unrelated (n = 20) donor. The probabilities of nonrelapse mortality, relapse, and disease-free survival (DFS) 2 years after the second BMT were 51%, 26%, and 23%, respectively. The 2-year DFS estimates for AML, ALL, and lymphoma were 46%, 23%, and 0%. Univariate analysis demonstrated that superior DFS was associated with age < or =17 years at the time of the second transplantation, remission before the second transplantation, total-body irradiation-based preparative regimen for the second transplantation, and the diagnosis of AML. These data demonstrate that an allogeneic transplantation after a failed autologous transplantation can result in disease-free survivors, especially in the young. The outcomes after a second transplantation for patients aged >17 years and for those with lymphoma were especially grim. These data suggest that pediatric patients may be appropriate candidates for a second transplantation. In adults, however, the use of an allogeneic transplantation as salvage therapy after failure of the initial autologous transplantation is generally unsuccessful. Alternative experimental strategies, such as low-dose nonmyeloablative allogeneic minitransplantations, should be considered. more...
- Published
- 2000
- Full Text
- View/download PDF
19. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation.
- Author
-
Flowers ME, Leisenring W, Beach K, Riddell S, Radich JP, Higano CS, Rowley SD, Chauncey TR, Sanders JE, Anasetti C, Storb R, Wade J, Appelbaum FR, and Martin P
- Subjects
- Adolescent, Adult, Anemia, Aplastic etiology, Biomarkers, Tumor analysis, Child, Combined Modality Therapy, Female, Fusion Proteins, bcr-abl blood, Graft vs Host Disease etiology, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Male, Middle Aged, Neoplasm Proteins blood, Recurrence, Treatment Outcome, Anemia, Aplastic prevention & control, Blood Component Removal, Blood Donors, Bone Marrow Transplantation, Graft Rejection, Granulocyte Colony-Stimulating Factor therapeutic use, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Leukocyte Transfusion adverse effects, Premedication, Salvage Therapy
- Abstract
We conducted 2 sequential studies of donor leukocyte infusion (DLI) in 26 patients with chronic myeloid leukemia in hematologic relapse after unmodified allogeneic bone marrow transplantation. In the first study, cells for DLI were collected from 13 donors who were not treated with granulocyte colony-stimulating factor (G-CSF) (group 1). In the second study, cells were collected from 13 donors who received G-CSF before apheresis (group 2) in an attempt to avoid aplasia after DLI. Patients in group 2 received 550-fold more CD34+ cells than those in group 1. We found no significant difference in the incidence (31% versus 22%), onset time (41 vs. 48 days), or duration (15 vs. 14 days) of cytopenia after DLI in the 2 groups. G-CSF given to donors before collection of cells did not prevent aplasia. These findings support the hypothesis that the pathogenesis of aplasia after DLI is not restricted to the destruction of recipient hematopoietic cells but also involves failure of donor hematopoiesis by undefined mechanisms. more...
- Published
- 2000
- Full Text
- View/download PDF
20. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.
- Author
-
Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, Storb R, and Thomas ED
- Subjects
- Busulfan therapeutic use, Combined Modality Therapy, Cyclophosphamide therapeutic use, Follow-Up Studies, Humans, Survival Analysis, Time Factors, Transplantation, Homologous, Whole-Body Irradiation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
- Published
- 1999
21. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.
- Author
-
Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW, van Burik JA, Flowers ME, Storb R, Appelbaum FR, and Hansen JA
- Subjects
- Adolescent, Adult, Anemia, Aplastic mortality, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation methods, Cause of Death, Child, Cyclophosphamide therapeutic use, Female, HLA-A Antigens immunology, HLA-B Antigens immunology, HLA-DR Antigens immunology, HLA-DRB1 Chains, Hematologic Neoplasms mortality, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Survival Analysis, Whole-Body Irradiation, Anemia, Aplastic therapy, Bone Marrow Transplantation immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Hematologic Neoplasms therapy, Histocompatibility Testing, Lymphocyte Depletion adverse effects
- Abstract
We conducted a phase I-II clinical trial to test the hypothesis that removal of CD4 cells from an HLA-mismatched unrelated marrow graft would substantially reduce the risk of grades III-IV graft-versus-host disease (GVHD) and that retention of a specified number of CD8 cells in the graft would be sufficient to prevent rejection. Patients were eligible for this study when an HLA-A, -B, or -DRB1-matched unrelated donor could not be identified. HLA matching of the donor and recipient was based on typing of HLA-A and -B antigens by serologic methods and by typing of HLA-DRB1 alleles by molecular methods, and donors were selected when disparity was limited to a single HLA-DRB1 allele or a single HLA-A or -B antigen. Twenty-seven patients with hematologic malignancy or aplastic anemia were prepared to receive a transplant with conventional regimens of cyclophosphamide and fractionated total body irradiation, and a standard regimen of methotrexate and cyclosporine was given for GVHD prophylaxis. CD4 cells were removed from the donor marrow, and the numbers of CD8 cells were adjusted systematically in graded steps for successive patients, depending on the occurrence of grades III-IV GVHD or graft failure in previously enrolled patients. Removal of CD4 cells did not cause graft rejection or appreciably decrease the risk of grades III-IV GVHD. Depletion of CD8 cells was associated with an increased risk of rejection with either HLA-DRB1 disparity or with HLA-A or -B disparity. With either type of disparity, the risk of grades III-IV GVHD is likely to be higher than 15% at any dose of CD8 cells associated with less than 5% risk of graft failure. The absence of graft failure associated with CD4 depletion supports the hypothesis that donor CD4 cells are not essential for preventing marrow graft rejection in humans. The correlation between graft failure and the number of CD8 cells in the donor marrow supports the hypothesis that donor CD8 cells help to prevent marrow graft rejection. more...
- Published
- 1999
22. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
- Author
-
Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, and Tura S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Busulfan adverse effects, Busulfan therapeutic use, Combined Modality Therapy, Humans, Hydroxyurea adverse effects, Hydroxyurea therapeutic use, Interferon-alpha adverse effects, Interferon-alpha therapeutic use, Transplantation, Homologous, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Evidence-Based Medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
- Abstract
Because there are differing opinions regarding treatment of patients in the chronic phase of chronic myeloid leukemia (CML), the American Society of Hematology convened an expert panel to review and document evidence-based benefits and harms of treatment of CML with busulfan (BUS), hydroxyurea (HU), recombinant interferon-alpha (rIFN-alpha), and bone marrow transplantation (BMT). The primary measure for defining efficacy was survival. Analysis indicated a survival advantage for HU over BUS. Observational studies of rIFN-alpha suffer from numerous biases including sample size, variations in study populations, definitions of hematologic and cytogenetic remissions, and dose. That rIFN-alpha is more efficacious than chemotherapy is demonstrated by 6 prospective randomized trials. For patients with favorable clinical features in chronic phase, compared to HU and BUS, rIFN-alpha improves survival by a median of about 20 months. Most evidence suggests that rIFN-alpha is most effective when combined with other drugs and when given during the earliest stage of the chronic phase. Adding cytarabine to rIFN-alpha adds further survival benefit but increases toxicity. Limitations for evaluating the long-term benefits of allogeneic BMT include the retrospective nature of most studies, incomplete documentation of the clinical characteristics of the patients, paucity of the details on patient selection, lack of control groups, and limitations of survival calculations. Survival curves for BMT show that at least half of the patients transplanted remain alive 5 to 10 years after treatment, whereas similar curves for rIFN-alpha show a continuous relapse rate over time with the curves crossing at about 7 to 8 years. Estimates of long-term survival may be confounded by the selection biases mentioned and the analytic methods used. The magnitude of the incremental increase in benefit with BMT must be weighed against the potential serious harm and death that may accompany the procedure in the short term. The best results with BMT have been obtained when it is performed within 1 to 2 years from diagnosis. Since each treatment option involves tradeoffs between benefit and harm, patient choice must be based on the examination of facts presented in an unbiased fashion. Newly diagnosed younger patients and older patients who are candidates for BMT should also be offered information about IFN-based regimens, the tradeoffs involved, and, if possible, share in the treatment decision. Hopefully this analysis will provide the stimulus for evaluation of other important aspects of CML. more...
- Published
- 1999
23. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.
- Author
-
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R, and Bernstein ID
- Subjects
- Acute Disease, Adolescent, Adult, Combined Modality Therapy, Disease-Free Survival, Female, Graft Survival, Humans, Iodine Radioisotopes, Leukemia immunology, Male, Middle Aged, Myelodysplastic Syndromes immunology, Transplantation, Autologous, Transplantation, Homologous, Antibodies administration & dosage, Antineoplastic Agents, Alkylating administration & dosage, Bone Marrow Transplantation, Cyclophosphamide administration & dosage, Leukemia drug therapy, Leukemia radiotherapy, Leukocyte Common Antigens immunology, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes radiotherapy, Whole-Body Irradiation
- Abstract
Delivery of targeted hematopoietic irradiation using radiolabeled monoclonal antibody may improve the outcome of marrow transplantation for advanced acute leukemia by decreasing relapse without increasing toxicity. We conducted a phase I study that examined the biodistribution of (131)I-labeled anti-CD45 antibody and determined the toxicity of escalating doses of targeted radiation combined with 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI) followed by HLA-matched related allogeneic or autologous transplant. Forty-four patients with advanced acute leukemia or myelodysplasia received a biodistribution dose of 0.5 mg/kg (131)I-BC8 (murine anti-CD45) antibody. The mean +/- SEM estimated radiation absorbed dose (centigray per millicurie of (131)I) delivered to bone marrow and spleen was 6.5 +/- 0.5 and 13.5 +/- 1.3, respectively, with liver, lung, kidney, and total body receiving lower amounts of 2.8 +/- 0.2, 1.8 +/- 0.1, 0.6 +/- 0.04, and 0.4 +/- 0.02, respectively. Thirty-seven patients (84%) had favorable biodistribution of antibody, with a higher estimated radiation absorbed dose to marrow and spleen than to normal organs. Thirty-four patients received a therapeutic dose of (131)I-antibody labeled with 76 to 612 mCi (131)I to deliver estimated radiation absorbed doses to liver (normal organ receiving the highest dose) of 3.5 Gy (level 1) to 12.25 Gy (level 6) in addition to CY and TBI. The maximum tolerated dose was level 5 (delivering 10.5 Gy to liver), with grade III/IV mucositis in 2 of 2 patients treated at level 6. Of 25 treated patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 7 survive disease-free 15 to 89 months (median, 65 months) posttransplant. Of 9 treated patients with acute lymphoblastic leukemia (ALL), 3 survive disease-free 19, 54, and 66 months posttransplant. We conclude that (131)I-anti-CD45 antibody can safely deliver substantial supplemental doses of radiation to bone marrow (approximately 24 Gy) and spleen (approximately 50 Gy) when combined with conventional CY/TBI. more...
- Published
- 1999
24. Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models.
- Author
-
Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, and Bernstein ID
- Subjects
- Absorption, Animals, Graft Survival, H-2 Antigens analysis, H-2 Antigens immunology, Kinetics, Male, Mice, Rats, T-Lymphocytes, Whole-Body Irradiation, Antibodies, Monoclonal administration & dosage, Bone Marrow Purging, Bone Marrow Transplantation, Immunosuppression Therapy, Iodine Radioisotopes pharmacokinetics, Leukocyte Common Antigens immunology
- Abstract
Targeted hematopoietic irradiation delivered by 131I-anti-CD45 antibody has been combined with conventional marrow transplant preparative regimens in an effort to decrease relapse. Before increasing the proportion of therapy delivered by radiolabeled antibody, the myeloablative and immunosuppressive effects of such low dose rate irradiation must be quantitated. We have examined the ability of 131I-anti-CD45 antibody to facilitate engraftment in Ly5-congenic and H2-mismatched murine marrow transplant models. Recipient B6-Ly5(a) mice were treated with 30F11 antibody labeled with 0.1 to 1.5 mCi 131I and/or total body irradiation (TBI), followed by T-cell-depleted marrow from Ly5(b)-congenic (C57BL/6) or H2-mismatched (BALB/c) donors. Engraftment was achieved readily in the Ly5-congenic setting, with greater than 80% donor granulocytes and T cells after 0.5 mCi 131I (estimated 17 Gy to marrow) or 8 Gy TBI. A higher TBI dose (14 Gy) was required to achieve engraftment of H2-mismatched marrow, and engraftment occurred in only 3 of 11 mice receiving 1.5 mCi 131I delivered by anti-CD45 antibody. Engraftment of H2-mismatched marrow was achieved in 22 of 23 animals receiving 0.75 mCi 131I delivered by anti-CD45 antibody combined with 8 Gy TBI. Thus, targeted radiation delivered via 131I-anti-CD45 antibody can enable engraftment of congenic marrow and can partially replace TBI when transplanting T-cell-depleted H2-mismatched marrow. more...
- Published
- 1999
25. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
- Author
-
Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, and Wiernik PH
- Subjects
- Acute Disease, Adolescent, Adult, Disease-Free Survival, Follow-Up Studies, Humans, Leukemia, Myeloid mortality, Middle Aged, Remission Induction, Survival Analysis, Transplantation Conditioning, Transplantation, Autologous, Transplantation, Homologous, Antimetabolites, Antineoplastic therapeutic use, Bone Marrow Transplantation, Cytarabine therapeutic use, Leukemia, Myeloid drug therapy, Leukemia, Myeloid therapy
- Abstract
Background: In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia., Methods: Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival., Results: In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04)., Conclusions: A postinduction course of high-dose cytarabine can provide equivalent disease-free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia. more...
- Published
- 1998
- Full Text
- View/download PDF
26. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.
- Author
-
Woolfrey AE, Gooley TA, Sievers EL, Milner LA, Andrews RG, Walters M, Hoffmeister P, Hansen JA, Anasetti C, Bryant E, Appelbaum FR, and Sanders JE
- Subjects
- Acute Disease, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation mortality, Cause of Death, Disease-Free Survival, Female, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Graft vs Host Disease prevention & control, Growth Disorders etiology, Humans, Infant, Karnofsky Performance Status, Leukemia, Myeloid mortality, Male, Myelodysplastic Syndromes mortality, Recurrence, Remission Induction, Retrospective Studies, Salvage Therapy, Survival Analysis, Survival Rate, Transplantation Conditioning adverse effects, Transplantation, Homologous, Treatment Failure, Treatment Outcome, Bone Marrow Transplantation methods, Leukemia, Myeloid therapy, Myelodysplastic Syndromes therapy
- Abstract
We analyzed results of 40 infants less than 2 years of age who received bone marrow transplants (BMT) between May 1974 and January 1995 for treatment of acute myelogenous leukemia (AML; N = 34) or myelodysplastic syndrome (MDS; N = 6) to determine outcome and survival performance. Among the AML patients, 13 were in first remission, 9 were in untreated first relapse or second remission, and 12 were in refractory relapse. Patients were conditioned with cyclophosphamide in combination with either total body irradiation (TBI; N = 29) or busulfan (N = 11). Source of stem cells included 6 autologous donors, 15 HLA genotypically identical siblings, 14 haploidentical family members, and 5 unrelated donors. Graft-versus-host disease (GVHD) prophylaxis was methotrexate (MTX) for 17, MTX plus cyclosporine (CSP) for 14, or CSP plus prednisone for 3. Incidence of severe (grade 3-4) regimen-related toxicity was 10% and transplant-related mortality was 10%. Acute GVHD (grades II-III) occurred in 39% of allogeneic patients, and chronic GVHD developed in 40%. Relapse, the most significant problem for patients in this study, occurred in 1 MDS patient and 23 AML patients and was the cause of death for 19 patients. The 2-year probabilities of relapse are 46%, 67%, and 92%, respectively, for patients transplanted in first remission, untreated first relapse or second remission, and relapse. One MDS and 8 AML patients received second marrow transplants for treatment of relapse, and 5 of these survive disease-free for more than 1.5 years. All 6 MDS patients and 11 of 34 AML patients survive more than 1.5 years later. The 5-year probabilities of survival and disease-free survival are 54% and 38% for patients transplanted in first remission and 33% and 22% for untreated first relapse or second remission. None of the patients transplanted with refractory relapse survive disease-free. Outcome was significantly associated with phase of disease at transplantation and pretransplant diagnosis of extramedullary disease. Long-term sequelae included growth failure and hormonal deficiencies. Survival performance was a median of 100% (80% to 100%) and neurologic development for all survivors was appropriate for age. This study indicates that infants with AML have similar outcome after BMT compared with older children and that BMT should be performed in first remission whenever possible. In addition, allogeneic BMT provides effective therapy for the majority of infants with MDS. more...
- Published
- 1998
27. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
- Author
-
Appelbaum FR and Anderson J
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Karyotyping, Male, Middle Aged, Multivariate Analysis, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes epidemiology, Prognosis, Recurrence, Retrospective Studies, Risk Factors, Treatment Outcome, Bone Marrow Transplantation, Myelodysplastic Syndromes therapy
- Abstract
The objective of our analysis was to determine the post-transplantation outcomes for patients with myelodysplastic syndrome (MDS) according to their International Prognostic Scoring System (IPSS) risk categorization. Data for all MDS patients transplanted at our institution from 1981-1996 were reviewed. Multivariate analysis was used to determine factors predictive for non-relapse mortality, relapse, and disease-free survival. A total of 251 MDS patients (median age = 38 years) were transplanted from 1981-1996. The overall disease-free survival rate was 40%, with an 18% relapse rate. Older age, increasing disease duration, mismatched donors, male gender, and therapy-related MDS were factors that significantly enhanced the likelihood of non-relapse mortality. Increasing disease duration, morphology, and cytogenetics were significant in predicting relapses. Increasing age, disease morphology, and cytogenetics were significant in determining disease-free survival. IPSS score was found to correlate significantly with relapse and disease-free survival. The 5-year disease-free survival was 60%, 36%, and 28% for low and intermediate-1 risk, intermediate-2 risk, and high risk patients, respectively. We conclude that IPSS score may be used to predict relapse and disease-free survival in MDS patients undergoing allogeneic transplantation. Allogeneic transplantation may be recommended for patients with intermediate-1, intermediate-2, or high risk MDS. more...
- Published
- 1998
28. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.
- Author
-
Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, and Slattery JT
- Subjects
- Aldehyde Dehydrogenase metabolism, Area Under Curve, Cyclophosphamide blood, Cyclophosphamide urine, Erythrocytes enzymology, Humans, Hydroxylation, Immunosuppressive Agents blood, Immunosuppressive Agents urine, Time Factors, Bone Marrow Transplantation, Cyclophosphamide pharmacokinetics, Immunosuppressive Agents pharmacokinetics
- Abstract
Objectives: To characterize the pharmacokinetics of cyclophosphamide and 5 of its metabolites in bone marrow transplant patients and to identify the mechanism of the increase in 4-hydroxycyclophosphamide area under the plasma concentration-time curve (AUC) from day 1 to day 2 of cyclophosphamide administration., Methods: Cyclophosphamide was administered by intravenous infusion (60 mg/kg over 1 hour, once a day) for 2 consecutive days to 18 patients. Cyclophosphamide and 4-hydroxycyclophosphamide concentration time data on day 1 and day 2 were fitted to a model to estimate 4-hydroxycyclophosphamide formation (CLf) and elimination (CLm) clearances. Erythrocyte aldehyde dehydrogenase-1 activity was measured ex vivo just before the first cyclophosphamide infusion was started (0 hours) and 24 hours after the second cyclophosphamide infusion (48 hours)., Results: From day 1 to day 2, the AUC of cyclophosphamide, deschloroethyl cyclophosphamide and phosphoramide mustard decreased 24.8%, 51%, and 29.4% (P < .02), the AUC of 4-hydroxycyclophosphamide and carboxyethylphosphoramide mustard increased 54.7% and 25% (P < .01), whereas the AUC of phosphoramide mustard was not significantly changed (P > .3). The CLf of 4-hydroxycyclophosphamide increased 60% (P < .001), its CLm decreased 27.7% (P < .001), and the fraction of cyclophosphamide dose converted to 4-hydroxycyclophosphamide increased 16% (P < .001) from day 1 to day 2. The activity of patient erythrocyte aldehyde dehydrogenase-1 decreased 23.3% (P < .02) from 0 hours to 48 hours., Conclusions: The AUC of 4-hydroxycyclophosphamide increased from day 1 to day 2 as a result of increased formation and decreased elimination clearances of 4-hydroxycyclophosphamide. Aldehyde dehydrogenase-1 activity appears to decline as a consequence of cyclophosphamide administration. more...
- Published
- 1998
- Full Text
- View/download PDF
29. Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.
- Author
-
Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, and Thomas ED
- Subjects
- Acute Disease, Bronchiolitis Obliterans etiology, Carcinoma, Bronchogenic, Cyclophosphamide therapeutic use, Disease-Free Survival, Dose-Response Relationship, Radiation, Follow-Up Studies, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Humans, Leukemia, Myeloid mortality, Life Tables, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local therapy, Neoplasms, Second Primary, Radiotherapy Dosage, Remission Induction, Survival Analysis, Transplantation Conditioning adverse effects, Transplantation, Homologous, Treatment Outcome, Whole-Body Irradiation adverse effects, Bone Marrow Transplantation adverse effects, Leukemia, Myeloid therapy, Transplantation Conditioning methods, Whole-Body Irradiation methods
- Published
- 1998
30. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer.
- Author
-
Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, and Appelbaum F
- Subjects
- Adolescent, Adult, Analysis of Variance, Child, Child, Preschool, Clinical Trials as Topic, Communicable Diseases complications, Communicable Diseases immunology, Female, Humans, Leukemia complications, Leukemia immunology, Leukocyte Count, Lymphoma complications, Lymphoma immunology, Male, Middle Aged, Neutrophils, Opportunistic Infections complications, Opportunistic Infections immunology, Recombinant Proteins, Retrospective Studies, Statistics, Nonparametric, Transplantation, Autologous, Bone Marrow Transplantation, Communicable Diseases epidemiology, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Leukemia therapy, Lymphoma therapy, Opportunistic Infections epidemiology
- Abstract
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) significantly shortens the number of days required to achieve an absolute neutrophil count of >500/mm3 after autologous bone marrow transplantation (ABMT); however, the ability of rhGM-CSF to enhance neutrophil and macrophage function in vivo has been incompletely characterized. In this retrospective study, the authors compared the incidence of infection from the day of transplantation to 28 days posttransplantation between two groups of previously studied patients who underwent ABMT at the Fred Hutchinson Cancer Research Center. A control group that received no cytokine was compared with a study group that received rhGM-CSF while participating in phase I, II, or III trials. During the posttransplantation period when both study groups had severe neutropenia, 40% (38 of 95) of control patients were found to have an infection, whereas only 13% (6 of 46) of rhGM-CSF patients developed an infection (p = 0.001). Most infections occurred before an absolute neutrophil count of > 100/mm3 was achieved. There was a trend toward fewer fungal infections (14% vs. 4%; p = 0.093); gram-negative bacterial infections (6% vs. 0%; p = 0.083); pulmonary infections (12% vs. 2%; p = 0.062); fewer days of amphotericin B (p = 0.0305); and fewer days of intravenous antibiotics (p = 0.0791) in rhGM-CSF-treated patients. These results support in vivo findings that the function-enhancing effect of rhGM-CSF may reduce infection-related complications. more...
- Published
- 1998
- Full Text
- View/download PDF
31. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.
- Author
-
Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, and Anasetti C
- Subjects
- Adolescent, Adult, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Leukemia, Myelogenous, Chronic, BCR-ABL Positive physiopathology, Male, Middle Aged, Survival Analysis, Transplantation, Homologous, Bone Marrow Transplantation, Graft Rejection prevention & control, Interferon-alpha administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
- Abstract
Treatment options for patients diagnosed with chronic myelogenous leukemia (CML) in chronic phase (CP) who lack a suitable related donor for marrow transplantation include hydroxyurea, interferon-alpha (IFN-alpha), or transplantation from an unrelated donor (URD). Most studies support the view that treatment with IFN-alpha results in prolonged survival compared with hydroxyurea therapy. Some patients are offered URD transplantation as a second-line treatment; however, the impact of pretransplant IFN-alpha on the outcome of URD transplantation is uncertain. To address this question, we evaluated the effect of pretransplant IFN-alpha therapy in 184 patients undergoing URD transplantation for CML in CP at a single center. Of the 184 patients, 114 did not receive IFN-alpha, whereas 22, 23, and 25 patients received IFN-alpha for, respectively, 1 to 5, 6 to 12, and more than 12 months before transplant. Pretransplant IFN-alpha therapy administered for > or = 6 months was associated with an increased risk of severe (grades III-IV) acute graft-versus-host disease (GVHD; relative risk [RR], 3.0; 95% confidence interval [CI], 1.4 to 6.2; P = .004) and mortality (RR, 2. 1; 95% CI, 1.3 to 3.5; P = .003) relative to less than 6 months or no IFN-alpha therapy. Increased mortality occurred between 100 and 365 days after transplant (P = .005), was limited to patients with severe acute GVHD, and was due to chronic GVHD refractory to immunosuppressive therapy. Other variables associated with mortality included HLA-DRB1 or DQB1 (but not HLA-A or B) mismatched donors, age greater than 50 years, weight > or = 110% of ideal body weight, and the absence of cytomegalovirus (CMV) or fungal prophylaxis. For patients treated with IFN-alpha for less than 6 months before transplant, who were < or = 50 years of age, received a HLA-A, B, DRB1, and DQB1 matched URD transplant, and received CMV and fungal prophylaxis after transplant (n = 48), survival was 87% +/- 5% at 5 years. These data provide a rationale for immediate transplantation in preference to extended treatment with IFN-alpha when the patient is < or = 50 years of age and has an HLA-compatible unrelated volunteer donor. more...
- Published
- 1998
32. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry.
- Author
-
Sullivan KM, Anasetti C, Horowitz M, Rowlings PA, Petersdorf EW, Martin PJ, Clift RA, Walters MC, Gooley T, Sierra J, Anderson JE, Bjerke J, Siadak M, Flowers ME, Nash RA, Sanders JE, Appelbaum FR, Storb R, and Hansen JA more...
- Subjects
- Histocompatibility Testing, Humans, International Agencies, Leukemia mortality, Living Donors, Survival Rate, Thalassemia mortality, Tissue Donors, Washington, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Leukemia therapy, Registries, Thalassemia therapy, Tissue and Organ Procurement organization & administration
- Abstract
Allogeneic marrow transplantation is curative therapy for thalassemia, but fewer than 30% of patients have an HLA-identical sibling marrow donor. Selection of alternative donors of hematopoietic stem cells (unrelated individuals or HLA-nonidentical family members) has been aided by establishment of world-wide donor registries now exceeding 3.6 million volunteers and by DNA-based HLA typing to more closely match potential donors. Coupled with improved methods to control graft-versus-host disease and prevent fungal and cytomegalovirus infection, remarkable progress has been made in alternative donor transplantation. For patients 50 years of age or younger, with recently diagnosed chronic myelogenous leukemia (CML) in chronic phase, 1- and 5-year survivals after HLA-A, B, DRB1 identical unrelated marrow transplantation in Seattle are 82% and 74%, respectively. These results are essentially identical to outcome in similar patients given HLA-matched sibling allografts. However, the world-wide number of alternative donor transplants for thalassemia remains limited to date: 4 unrelated and 60 HLA-nonidentical related transplants have been reported to the IBMTR since 1969 with actuarial overall survival of 75%. Using the paradigm of CML, it is likely that access to curative therapy of thalassemia will improve with optimal HLA typing and donor selection early in the course of disease. more...
- Published
- 1998
- Full Text
- View/download PDF
33. Bone marrow transplantation for myelodysplasia in adults and children: when and who?
- Author
-
Appelbaum FR and Anderson J
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Disease-Free Survival, Humans, Infant, Karyotyping, Middle Aged, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes mortality, Risk Factors, Survival Rate, Bone Marrow Transplantation, Myelodysplastic Syndromes therapy
- Published
- 1998
- Full Text
- View/download PDF
34. Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model.
- Author
-
Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, and Santos EB
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Monoclonal immunology, Antibody Affinity, Antibody Specificity, Cloning, Molecular, Epitope Mapping, Graft Rejection prevention & control, Killer Cells, Natural immunology, Molecular Sequence Data, Sequence Alignment, Sequence Homology, Amino Acid, Whole-Body Irradiation, Antibodies, Monoclonal therapeutic use, Bone Marrow Transplantation methods, Dogs immunology, Hyaluronan Receptors physiology
- Abstract
Primary graft rejection after marrow transplantation occurs more frequently in patients receiving HLA-haploidentical compared with HLA-identical sibling transplants. Both human and experimental animal data suggest that the cells responsible for this phenomenon are either host natural killer (NK) cells, T cells, or both. To investigate the mechanisms of graft rejection, we have developed a canine model of marrow transplantation, which uses DLA-nonidentical unrelated donors in the absence of postgrafting immunosuppression. In this model most animals rejected their marrow grafts after a preparative regimen of 9.2 Gy total body irradiation (TBI). However, engraftment of DLA-nonidentical marrow can be facilitated when the recipients are pretreated with monoclonal antibody (MoAb) S5, which recognizes CD44. In this report, we extended these observations by first cloning the canine CD44 and, next, mapping the epitope recognized by S5, which was located in a region conserved among human and canine CD44 and was distinct from the hyaluronan binding domain. However, in vitro binding of S5 caused a conformational change in CD44, which allowed increased hyaluronan binding. Then, we reexamined the in vivo model of marrow transplantation and compared results with MoAb S5 to those with two other anti-CD44 MoAbs, IM7 and S3. Only MoAb S5 significantly increased the engraftment rate of DLA-nonidentical unrelated marrow, whereas the two other anti-CD44 MoAbs were ineffective. The enhanced in vivo effect was not related to differences in the MoAbs' avidities, since both S5 and IM7 had equivalent binding to CD44, but most likely related to the specific epitope that S5 recognizes. Thus, this study shows that the effect of the anti-CD44 MoAb S5 in facilitating engraftment is epitope specific and if one is to use an anti-CD44 to facilitate engraftment of marrow in humans, one cannot assume that any anti-CD44 would work. more...
- Published
- 1998
35. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.
- Author
-
Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, and Anasetti C
- Subjects
- Adolescent, Adult, Child, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Leukemia, Myeloid, Chronic-Phase mortality, Male, Middle Aged, Proportional Hazards Models, Recurrence, Survival Analysis, Time Factors, Bone Marrow Transplantation immunology, Leukemia, Myeloid, Chronic-Phase therapy, Tissue Donors
- Abstract
Background: Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome., Methods: Between May 1985 and December 1994, 196 patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors., Results: The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients who could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at five years was 10 percent. The Kaplan-Meier estimate of survival at five years was 57 percent. Survival was adversely affected by an interval from diagnosis to transplantation of one year or more, an HLA-DRB1 mismatch, a high body-weight index, and an age of more than 50 years. Survival was improved by the prophylactic use of fluconazole and ganciclovir. The Kaplan-Meier estimate of survival at five years was 74 percent (95 percent confidence interval, 62 to 86 percent) for patients who were 50 years of age or younger who received a transplant from an HLA-matched donor within one year after diagnosis., Conclusions: Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia. more...
- Published
- 1998
- Full Text
- View/download PDF
36. Dose rate-dependent sparing of the gastrointestinal tract by fractionated total body irradiation in dogs given marrow autografts.
- Author
-
Storb R, Raff R, Deeg HJ, Graham T, Appelbaum FR, Schuening FG, Shulman H, Seidel K, and Leisenring W
- Subjects
- Animals, Dogs, Dose-Response Relationship, Radiation, Transplantation, Autologous, Bone Marrow Transplantation, Digestive System radiation effects, Dose Fractionation, Radiation, Whole-Body Irradiation mortality
- Abstract
Purpose: We compared gastrointestinal toxicity of single vs. fractionated total body irradiation (TBI) administered at dose rates ranging from 0.021 to 0.75 Gy/min in a canine model of marrow transplantation., Methods and Materials: Dogs were given otherwise marrow-lethal single or fractionated TBI from dual 60Co sources at total doses ranging from 8-18 Gy and delivered at dose rates of 0.021, 0.05, 0.10, 0.20, 0.40, and 0.75 Gy/min, respectively. They were protected from marrow death by infusion of previously stored autologous marrow cells and they were given intensive supportive care posttransplant. The study endpoint was 10-day mortality from gastrointestinal toxicity. Logistic regression analyses were used to jointly evaluate the effects of dose rate, total dose, and delivery regimen on toxicity., Results and Conclusion: With increasing dose rates, mortality increased for either mode of delivery of TBI. With dose rates through 0.10 Gy/min, mortality among dogs given single vs. fractionated TBI appeared comparable. Beginning at 0.20 Gy/min, fractionation appeared protective for the gastrointestinal tract. Results in dogs given TBI at 0.40 and 0.75 Gy/min, respectively, were comparable, and dose fractionation permitted the administration of considerably higher total doses of TBI than were possible after single doses, an increment that was on the order of 4.00 Gy. The data indicate that the impact of fractionating the total dose at high dose rates differs from the effect of fractionation at low dose rates. more...
- Published
- 1998
- Full Text
- View/download PDF
37. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation.
- Author
-
Martin P, Nash R, Sanders J, Leisenring W, Anasetti C, Deeg HJ, Storb R, and Appelbaum F
- Subjects
- Histocompatibility Testing, Humans, Reproducibility of Results, Retrospective Studies, Transplantation, Homologous, Bone Marrow Transplantation, Graft vs Host Disease classification, Graft vs Host Disease pathology
- Abstract
We have undertaken a formal study to evaluate the reproducibility of retrospective assessments for grading the severity of acute GVHD. Using criteria previously established by the Seattle group, three reviewers independently assigned GVHD severity grades for a set of 100 marrow transplant patients. Significant differences were found in the distribution of GVHD grades assigned by one of the reviewers as compared to the other two reviewers. In only 40% of cases did all three reviewers assign the same GVHD grade, and in only 68-71% of cases did all three reviewers assign the same grade within 0-I vs II-IV or 0-II vs III-IV categories. Despite the high rate of disagreement between any two reviewers, at least two reviewers assigned the same overall GVHD grade in 93% of cases. These results suggest that current criteria for assessing the severity of GVHD by a single reviewer are not sufficiently reliable for rigorous clinical studies. As an alternative to the original criteria, we have developed and tested simplified criteria that summarize the clinical course of GVHD as reflected by the progression of disease and the amount of immunosuppressive treatment used to control the disease. Our results suggest that the revised criteria might yield more reproducible retrospective grading than the original criteria. Although the original criteria and the revised criteria might produce different results for individual patients, the overall distributions of grades with the two systems were similar. The proposed revised criteria could be implemented without disrupting the continuity and consistency with previous grading assigned by the original criteria. more...
- Published
- 1998
- Full Text
- View/download PDF
38. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.
- Author
-
Sullivan KM, Kansu E, Storer B, Jocom J, Emerson G, Reagan T, Emerson V, Siadak MF, Davis C, Appelbaum FR, Buckner CD, Hansen JA, Shulman HM, Storb R, and McDonald GB
- Subjects
- Hepatic Veno-Occlusive Disease etiology, Humans, Multivariate Analysis, Randomized Controlled Trials as Topic, Retrospective Studies, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation adverse effects, Hepatic Veno-Occlusive Disease prevention & control, Immunoglobulins, Intravenous administration & dosage
- Abstract
Recent reports using historical controls or registry cohorts suggest, respectively, either an increase in the mortality or a decrease in the incidence of hepatic veno-occlusive disease (VOD) with the administration of intravenous immunoglobulin (i.v.Ig) after bone marrow transplantation. These divergent results prompted us to conduct a retrospective analysis of two randomized clinical trials conducted at our center to determine the effect of i.v.Ig infusions on the development and severity of VOD. Patients were randomized to receive (n=318) or not to receive (n=315) i.v.Ig prophylaxis after human leukocyte antigen-identical sibling (n=414), mismatched or unrelated (n=178), or autologous or syngeneic (n=41) marrow transplantation. To determine the relationship of i.v.Ig to the development and severity of VOD, a single observer reviewed data displays created for each patient for grading VOD without knowledge of patient i.v.Ig use. In this analysis, VOD was defined as hyperbilirubinemia > or =2.0 mg/dL before day 20 and abrupt weight gain > or =2% before day 14 posttransplant in the absence of other causes of liver disease. Hepatic VOD developed in 235 (37%) of the 633 randomized patients. No evidence for VOD was found in 230 (36%) patients. The remaining 168 (27%) patients were classified as having liver disease of uncertain etiology. Hepatic VOD was judged to be severe in 63 (10%) and mild or moderate in 172 (27%) patients. The number of patients developing any VOD or severe VOD was similar between those randomized to i.v.Ig prophylaxis and untreated controls (115 vs. 120 and 32 vs. 31, respectively). Logistic regression models identified several covariates as significant (p < 0.01) factors associated with the development of severe VOD. Increased risk occurred with elevated pretransplant serum aspartate aminotransferase (odds ratio [OR] = 2.64) and earlier year of transplant (OR = 3.73); decreased risk occurred with autologous or twin donors (OR = 0.09) and acute myeloid leukemia (OR = 0.39). The development of any VOD was associated with an elevated pretransplant alkaline phosphatase (OR = 4.1), pretransplant use of vancomycin (OR = 1.6) or amphotericin (OR = 3.0), posttransplant use of cyclosporine (OR = 2.5), older patient age (OR = 1.03), and obesity (OR = 0.78). We concluded from the controlled trials of 633 patients that the administration of i.v.Ig did not influence the development or severity of VOD after bone marrow transplantation. more...
- Published
- 1998
- Full Text
- View/download PDF
39. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation.
- Author
-
Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, and Sullivan KM
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Blood Banks, Child, Drug Administration Schedule, Health Care Surveys, Hematopoietic Stem Cell Transplantation, Humans, Neoplasms therapy, Surveys and Questionnaires, Tissue Banks, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Blood Transfusion, Bone Marrow Transplantation, Practice Patterns, Physicians', Societies, Scientific
- Abstract
Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey to identify errors in safety practices during the administration of high-dose chemotherapy. The questionnaire was returned from 115 (68%) of 170 hematopoietic transplant centers in the United States. Ninety-four of the programs were university or affiliated centers, 19 were community hospitals, and 41 were founded since 1990. A total of 7650 transplants were reported for 1994: 22% of the programs performed 1-20 transplants, 60% performed 21-100 transplants, and 18% performed more than 100 transplants. Fifteen of the 115 responding centers reported a total of 18 patients inadvertently given overdoses of cisplatin (n=3), carboplatin (n=2), busulfan (n=2), cytosine arabinoside (n=2), cyclophosphamide (n=2), interleukin-2 (n=2), or other agents (n=5) between 1989 and 1994. Cumulative drug doses given as a daily dose (six cases) and nursing infusion errors (six cases) were the most common errors. The estimated chemotherapy overdose error rate was 0.06%, or 6 cases/10,000 transplants, with 95% confidence limits of 0.03-0.11%. The overdose rate among more experienced centers in operation before 1990 was lower than that among newer centers (p < 0.01). Large centers (> 100 transplants performed in 1994) experienced errors at rates lower than those in medium-sized centers (21-100 transplants, p = 0.03). Although the number of events was small in this self-reporting survey, overdoses were noted in 13% of the responding centers, especially among more recently established units. Safety practices need to emphasize multidisciplinary checkpoints at the physician, pharmacist, nursing, and institutional levels. Based on these survey results, ASBMT recommendations for further safeguards for high-dose chemotherapy administration are proposed. more...
- Published
- 1997
40. Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs.
- Author
-
Schuening FG, von Kalle C, Kiem HP, Appelbaum FR, Deeg HJ, Pepe M, Gooley T, Graham TC, Hackman RC, and Storb R
- Subjects
- Animals, Bone Marrow Transplantation immunology, Dogs, Female, Graft Survival, Graft vs Host Disease etiology, Granulocyte Colony-Stimulating Factor pharmacology, Histocompatibility, Male, Recombinant Proteins pharmacology, Time Factors, Bone Marrow Transplantation veterinary, Hematopoiesis drug effects, Stem Cell Factor pharmacology
- Abstract
We studied the effect of recombinant canine stem cell factor (rcSCF) on hematopoietic recovery, incidence of graft failure, graft-vs.-host disease (GVHD), and survival after marrow transplantation from dog leukocyte antigen (DLA)-identical canine littermates. Ten animals received 100 microg rcSCF/kg/day b.i.d. by subcutaneous injection on days 1 through 10 after 920 cGy total body irradiation and transplantation of a mean of 3.7x10(8) marrow cells/kg body weight. None of the dogs received GVHD prophylaxis. All animals showed hematopoietic engraftment. The median number of days to achieve 1000 neutrophils/mm3 was 9; 100 monocytes/mm3 were reached after 15 days, 500 lymphocytes/mm3 after 21 days, and 20,000 platelets/mm3 after 16 days. One animal developed GVHD involving skin, gut, and liver and died of bacterial pneumonia 21 days after transplantation. The remaining nine dogs were observed for a median of 37 days (range 29-84 days) posttransplantation until they were killed. Facial edema was seen in three dogs during the first 2-3 days of rcSCF administration. These results show that within the limits of this study it appears to be safe to administer SCF after DLA-identical littermate marrow transplants in dogs. Comparison with previously published data in the same model showed that neutrophil and monocyte recovery was significantly faster in dogs receiving SCF treatment compared with dogs without growth factor treatment (recovery to achieve 1000 neutrophils/mm3: median 9 days vs. 13 days, p = 0.002; recovery to 100 monocytes/mm3: median 15 days vs. 105 days, p = 0.0002). Otherwise, no significant differences were seen. Results obtained with SCF treatment were similar to those previously obtained in the same model with recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment except that recovery of lymphocytes to 500/mm3 appeared to be more rapid in G-CSF-treated dogs (median 15 days vs. 21 days, p = 0.03). more...
- Published
- 1997
41. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
- Author
-
Anderson JE, Sale G, Appelbaum FR, Chauncey TR, and Storb R
- Subjects
- Adolescent, Adult, Bone Marrow Transplantation adverse effects, Female, Humans, Male, Middle Aged, Primary Myelofibrosis etiology, Recurrence, Survival Analysis, Survival Rate, Transplantation, Homologous, Bone Marrow Transplantation methods, Polycythemia Vera complications, Primary Myelofibrosis therapy, Thrombocythemia, Essential complications
- Abstract
Primary myelofibrosis is a clonal haemopoietic disorder, incurable with conventional therapy, and associated with a median survival of 4-5 years. Patients with polycythaemia vera and essential thrombocytosis who progress into a myelofibrotic picture also have a poor prognosis. Between 1980 and 1996, 13 patients with myelofibrosis due to one of these three myeloproliferative disorders (primary myelofibrosis [n=8], essential thrombocytosis [n=3], polycythaemia vera [n=2]) underwent allogeneic marrow transplantation in Seattle. The median age was 40 years (range 18-49). The median time from myeloproliferative diagnosis to transplantation was 39 months (range 5-192). Three patients received preparative regimens containing total body irradiation and 10 received busulphan-cyclophosphamide regimens. Nine patients received marrow from HLA-matched related donors, one from a one antigen mismatched related donor, and three from HLA-matched unrelated donors. The median time to both granulocyte and platelet engraftment was 21 d. Nine patients survive between 1.2 and 7.1 years post-transplant. Two patients relapsed at 1 year post-transplant, both of whom survive in a chronic myeloproliferative state. Four patients died of transplant-related complications between 43 d and 2.2 years post-transplant. At 1 year post-transplant the majority of the disease-free survivors have normal peripheral blood counts and none-to-minimal marrow fibrosis. These preliminary results are encouraging, and suggest that stem cell transplantation can be curative therapy for selected patients with myelofibrosis. more...
- Published
- 1997
- Full Text
- View/download PDF
42. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Author
-
Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, Bryant E, Nash RA, Sanders JE, Storb R, Sullivan KM, Appelbaum FR, and Anasetti C
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Histocompatibility Testing, Humans, Infant, Middle Aged, Outcome Assessment, Health Care, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Tissue Donors, Transplantation Conditioning, Bone Marrow Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Transplantation of marrow from unrelated donors was investigated in patients with Philadelphia chromosome-positive (Ph1+) acute lymphoblastic leukemia (ALL) who lacked a suitable family donor. Eighteen patients underwent transplantation at our center between 1988 and 1995. The median patient age was 25 years (range, 1.7 to 51 years). Seven patients were in first complete remission, 1 in second remission, 3 in first relapse, and the remaining 7 had more advanced or chemotherapy refractory leukemia at transplant. All patients were conditioned with cyclophosphamide and total body irradiation followed by marrow transplants from closely HLA-matched, unrelated volunteers. Posttransplant graft-versus-host disease (GVHD) prophylaxis included methotrexate with either cyclosporine or FK506. Graft failure was not observed. Severe (grades III-IV) GVHD appeared in 6 of 17 evaluable patients and chronic extensive GVHD in 7 of 13 patients at risk. Five patients had recurrent ALL after transplantation and another 4 died from causes other than leukemia. Six patients transplanted in first remission, 2 in first relapse, and 1 in second remission remain alive and leukemia-free at a median follow-up of 17 months (range, 9 to 73 months). The probability of leukemia-free survival at 2 years is 49% +/- 12%. These data indicate that unrelated donor marrow transplantation is an effective treatment option for patients with early stage Ph1+ ALL without a family match and suggest that in such patients an unrelated donor search should be initiated as soon as possible after diagnosis. more...
- Published
- 1997
43. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.
- Author
-
Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, and Anasetti C
- Subjects
- Acute Disease, Adolescent, Adult, Cell Count, Child, Child, Preschool, Female, Hematopoietic Stem Cells pathology, Humans, Infant, Male, Middle Aged, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation, Histocompatibility Testing, Leukemia therapy
- Abstract
Transplantation of hematopoietic stem cells from an HLA-compatible unrelated volunteer is an option for patients with acute leukemia lacking a family match. However, criteria for patient and donor selection and the most effective transplant procedures, including the number of hematopoietic cells, remain to be defined. We tested factors influencing outcome of 174 patients with primary acute leukemia receiving non-T-cell depleted marrow from unrelated donors. Median patient age was 20 years (range, 0.5 to 54 years). A multivariable analysis found that leukemia in remission at the time of transplantation was associated with improved leukemia-free survival (relative risk [RR] of treatment failure: 0.5, confidence interval [CI]: 0.3 to 0.7), and presence of blasts in the peripheral blood, as opposed to marrow involvement only or isolated extramedullary relapse, was associated with impaired outcome (RR of treatment failure: 2.5, CI: 1.7 to 5.0). The use of donors with a limited HLA-mismatch was associated with decreased leukemic relapse (RR: 0.5, CI: 0.3 to 0.9) but no improvement in leukemia-free survival compared with HLA-matched unrelated donors. Transplantation of a marrow cell dose above the median value of 3.65 x 10(8)/kg was associated with faster neutrophil (RR: 1.5, CI: 1.1 to 2.0) and platelet (RR: 4.5, CI: 2.7 to 7.5) engraftment, and decreased incidence of severe acute graft-versus-host disease (RR: 0.6, CI: 0.4 to 0.9). In patients transplanted in remission, the use of a marrow cell dose above the median translated into less nonleukemic death (RR: 0.2, CI: 0.1 to 0.4) and better leukemia-free survival (RR of treatment failure: 0.3, CI: 0.2 to 0.6). Transplant in remission with a high dose of marrow cells was associated with the best outcome in both children and adults. more...
- Published
- 1997
44. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.
- Author
-
Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, Chauncey T, Clift RA, Deeg HJ, Doney KC, Flowers ME, Hansen JA, Martin PJ, Sanders JE, Sullivan KM, and Witherspoon RP
- Subjects
- Adolescent, Adult, Anemia, Aplastic mortality, Child, Child, Preschool, Female, Follow-Up Studies, Graft Rejection, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology, Humans, Life Tables, Male, Middle Aged, Prevalence, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Alkylating Agents adverse effects, Anemia, Aplastic therapy, Antilymphocyte Serum adverse effects, Bone Marrow Transplantation adverse effects, Cyclophosphamide adverse effects, Immunosuppressive Agents adverse effects, T-Lymphocytes immunology, Transplantation Conditioning adverse effects
- Published
- 1997
45. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL).
- Author
-
Appelbaum FR
- Subjects
- Humans, Lymphocyte Depletion, T-Lymphocytes, Transplantation, Homologous, Transplantation, Isogeneic, Bone Marrow Transplantation immunology, Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
The ability of T cells that accompany or develop from transplanted allogeneic marrow to eradicate leukemia has been repeatedly demonstrated in animal models. Whether a similar graft-versus-leukemia effect exists in humans who have received transplants for acute lymphoblastic leukemia can be addressed by five different clinical observations: comparisons of autologous versus allogeneic transplantation, comparisons of syngeneic versus allogeneic transplantation, examination of relapse rates in allogeneic recipients who do or do not develop GVHD, the impact of T-cell depletion on relapse rates, and the results of donor lymphocyte infusions to treat posttransplant relapse. The bulk of available evidence supports the view that a potent GVL effect exists in patients treated for ALL. These results provide a strong rationale for efforts to develop techniques to further capitalize on the GVL effect. more...
- Published
- 1997
46. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
- Author
-
Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, and Appelbaum FR more...
- Subjects
- Adult, Busulfan administration & dosage, Busulfan adverse effects, Cause of Death, Cyclophosphamide administration & dosage, Female, Graft Rejection epidemiology, Graft vs Host Disease mortality, Humans, Infections etiology, Infections mortality, Leukemia, Myeloid, Accelerated Phase blood, Leukemia, Myeloid, Accelerated Phase mortality, Leukemia, Myeloid, Accelerated Phase pathology, Leukemia, Myeloid, Chronic-Phase blood, Leukemia, Myeloid, Chronic-Phase mortality, Leukemia, Myeloid, Chronic-Phase pathology, Male, Middle Aged, Neoplasm, Residual, Quality of Life, Recurrence, Remission Induction, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation mortality, Busulfan blood, Leukemia, Myeloid, Accelerated Phase therapy, Leukemia, Myeloid, Chronic-Phase therapy, Transplantation Conditioning adverse effects
- Abstract
The influence of busulfan (BU) plasma concentration on outcome of transplantation from HLA identical family members for the treatment of chronic myelogenous leukemia (CML) was examined in 45 patients transplanted in chronic phase (CP) (n = 39) or accelerated phase (AP) (n = 6). All patients received the same regimen of BU, 16 mg/kg orally and cyclophosphamide (CY), 120 mg/kg intravenously. Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient. The mean C(SS)BU was 917 ng/mL (range, 642 to 1,749; median, 917; standard deviation, 213). Of patients with C(SS)BU below the median, seven (five of 18 in CP and two of four in AP) developed persistent cytogenetic relapse and three of these patients died. There were no relapses in patients with C(SS)BU above the median. The difference in the cumulative incidence of relapse between the two groups was statistically significant (P = .0003). C(SS)BU was the only statistically significant determinant of relapse in univariable or multivariable analysis. The 3-year survival estimates were 0.82 and 0.64 for patients with C(SS)BU above and below the median (P = .33). There was no statistically significant association of C(SS)BU with survival or nonrelapse mortality, although the power to detect a difference in survival between 0.82 and 0.64 was only 0.24, similarly C(SS)BU above the median was not associated with an increased risk of severe regimen-related toxicity. We conclude that low BU plasma levels are associated with an increased risk of relapse. more...
- Published
- 1997
47. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.
- Author
-
Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, and Appelbaum FR
- Subjects
- Acute Disease, Adolescent, Adult, Biomarkers, Tumor genetics, Child, Child, Preschool, Disease-Free Survival, Female, Fusion Proteins, bcr-abl genetics, Graft vs Host Disease epidemiology, Humans, Infant, Male, Middle Aged, Neoplasm, Residual, Philadelphia Chromosome, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Recurrence, Risk, Treatment Failure, Biomarkers, Tumor analysis, Bone Marrow Transplantation, Fusion Proteins, bcr-abl analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
Thirty-six patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were studied for the presence of the bcr-abl fusion mRNA transcript after an allogeneic matched related (N = 12), partially matched related (N = 4), matched unrelated (N = 14), autologous (N = 5), or syngeneic (N = 1) bone marrow transplant (BMT). Seventeen were transplanted in relapse, and 19 were transplanted in remission. Twenty-three patients had at least one positive bcr-abl polymerase chain reaction (PCR) assay after BMT either before a relapse or without subsequent relapse. Ten of these 23 relapsed after a positive assay at a median time from first positive PCR assay of 94 days (range, 28 to 416 days). By comparison, only 2 relapses occurred in the 13 patients with no prior positive PCR assays; both patients had missed at least one scheduled follow-up assay and were not tested 2 months and 26 months before their relapse. The unadjusted relative risk (RR) of relapse associated with a positive PCR assay compared with a negative assay was 5.7 (95% confidence interval 1.2 to 26.0, P = .025). In addition, the data suggest that the type of bcr-abl chimeric mRNA detected posttransplant was associated with the risk of relapse: 7 of 10 patients expressing the p190 bcr-abl relapsed, compared with 1 of 8 who expressed only the p210 bcr-abl mRNA (P = .02, log-rank test). The RR of p190 bcr-abl positivity compared to PCR-negative patients was 11.2 (confidence interval 2.3-54.8, P = 0.003), whereas a positive test for p210 bcr-abl was apparently not associated with an increased relative risk. In separate multivariable models, PCR positivity remained a statistically significant risk factor for relapse after separately adjusting for donor (unrelated and partially matched v matched, autologous, and syngeneic), remission status at the time of transplant, the presence of acute graft-versus-host disease (GVHD), and type of conditioning regimen (total body irradiation dose of < or = 1,200 cGy v > 1,200 cGy). The PCR assay appears to be a useful test for predicting patients at high risk of relapse after BMT and may identify patients who might benefit from therapeutic interventions. The finding that the expression of p190 bcr-abl may portend an especially high risk of relapse suggests a different clinical and biologic behavior between p190 and p210 bcr-abl. more...
- Published
- 1997
48. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team.
- Author
-
Doney K, Leisenring W, Storb R, and Appelbaum FR
- Subjects
- Actuarial Analysis, Adolescent, Adult, Age Factors, Anemia, Aplastic immunology, Anemia, Aplastic mortality, Child, Child, Preschool, Female, Humans, Immunosuppressive Agents adverse effects, Infant, Leukocyte Count, Male, Middle Aged, Neutrophils, Prognosis, Retrospective Studies, Transplantation Conditioning, Anemia, Aplastic therapy, Bone Marrow Transplantation adverse effects, Immunosuppressive Agents therapeutic use
- Abstract
Background: Both immunosuppressive therapy and bone marrow transplantation are accepted treatments for patients with aplastic anemia. Choosing one of these therapies for a given patient depends not only on donor availability but also on such factors as patient age., Objective: To compare survival rates and long-term complications after bone marrow transplantation or immunosuppressive therapy in patients with acquired aplastic anemia and to identify prognostic factors associated with improved survival., Design: Center-based, retrospective analysis., Setting: Referral center for patients with aplastic anemia., Patients: 395 patients with acquired aplastic anemia., Intervention: Bone marrow transplant from an HLA-identical, related donor or immunosuppressive therapy., Measurements: Kaplan-Meier survival curves, results of log rank tests, and cumulative incidence curves., Results: Of 168 bone marrow transplant recipients, 89% had sustained engraftment. Forty-six patients developed grade II to IV acute graft-versus-host disease, and 68 developed chronic graft-versus-host disease that required therapy. Of 227 patients who received immunosuppressive therapy, 44% achieved a complete, partial, or minimal response. Fifty-four percent died or had no response to therapy. Actuarial survival at 15 years was 69% for bone marrow transplant recipients and 38% for patients receiving immunosuppressive therapy (P < 0.001). Improved survival was associated with having bone marrow transplantation as primary therapy, being younger, having no transfusion before transplantation, and having a higher absolute neutrophil count. Disease duration, year of therapy, sex, refractoriness to platelet transfusions, and previous treatment with androgens or corticosteroids did not significantly affect survival., Conclusions: Data from this center suggest that bone marrow transplantation may be preferred for younger patients with acquired aplastic anemia who have matched, related donors. Long-term survival is excellent for patients who respond to either form of therapy. more...
- Published
- 1997
- Full Text
- View/download PDF
49. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies.
- Author
-
Matthews DC, Appelbaum FR, Press OW, Eary JF, and Bernstein ID
- Subjects
- Antigens, CD immunology, Antigens, Differentiation, Myelomonocytic immunology, Cell Adhesion Molecules immunology, Clinical Protocols, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Hodgkin Disease therapy, Humans, Isotope Labeling, Leukocyte Common Antigens immunology, Membrane Glycoproteins immunology, Radioimmunotherapy, Sialic Acid Binding Ig-like Lectin 3, Antibodies, Bone Marrow Transplantation methods, Hematologic Neoplasms therapy
- Published
- 1997
- Full Text
- View/download PDF
50. The role of radioimmunotherapy in bone marrow transplantation.
- Author
-
Corcoran MC, Press OW, Matthews DC, Appelbaum FR, and Bernstein ID
- Subjects
- Clinical Trials as Topic, Female, Humans, Male, Bone Marrow Transplantation, Hematologic Neoplasms radiotherapy, Neoplasms radiotherapy, Radioimmunotherapy
- Abstract
Radioimmunotherapy offers an exciting new therapeutic modality for patients with recurrent hematologic malignancies and solid tumors resistant to conventional chemotherapy. In this review, a brief overview of tumor radiobiology as well as various obstacles to treatment is presented. Early radiolabeled antibody trials documented myelosuppression as the dose-limiting toxicity. Ongoing trials in solid tumors and hematologic malignancies are testing the hypothesis that myeloablative doses of radiation in conjunction with hematopoietic stem cell rescue will improve long-term survival. For solid tumors, there are many barriers to achieving this goal. The most encouraging trials in metastatic breast cancer have documented significant symptomatic relief and a 50% partial response in patients. In contrast, trials involving hematologic malignancies have produced more impressive results. With a median follow-up of 33 months, 67% of patients with recurrent acute myelogenous leukemia or myelodysplasia treated with radiolabeled antibodies, total-body irradiation, and high-dose chemotherapy remain disease free. Alone, myeloablative doses of radioimmunotherapy have documented a 41% complete response in patients with Hodgkin's disease. Seattle trials with recurrent non-Hodgkin's lymphoma have demonstrated objective responses in 90% of patients, complete responses in 85% of patients, a progression-free survival of 62%, and an overall survival of 93% with a median follow-up of 2 years. more...
- Published
- 1996
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.